Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.

ABSTRACT:

Background

The impact of pregnancy on efavirenz (EFV) pharmacokinetics is unknown.

Methods

International Maternal Pediatric Adolescent AIDS Clinical Trials P1026s is an on-going, prospective, nonblinded study of antiretroviral pharmacokinetics in HIV-infected pregnant women that included a cohort receiving 600 mg EFV once daily as part of combination antiretroviral therapy. Intensive steady-state 24-hour blood sampling was performed during the third trimester and at 6-12 weeks postpartum. Maternal and umbilical cord blood samples were drawn at delivery. Pharmacokinetics targets were the estimated 10th percentile EFV area under the curve (AUC) in nonpregnant historical controls (40.0 mcg·hr(-1)·mL(-1)) and a trough concentration of 1 mcg/mL.

Results

Twenty-five women w

SUBMITTER: Cressey TR 

PROVIDER: S-EPMC3288559 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature